Iambic Therapeutics Inc. (IAM)
IAM trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | IAM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001997038 |
| SEC industry code | Biological Products, (No Diagnostic Substances) (SEC code, stale: periodic reports ended never filed) |
| Incorporated in | DE |
Financials
No annual revenue in SEC XBRL data for this filer.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No recent periodic report | None on EDGAR |
| Cash and burn | no XBRL financials | None on EDGAR |
| Shares outstanding | No cover-page share count in XBRL | None on EDGAR |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Diego, California, United States | PCAOB Form AP 2026-10-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| SEC reporting | The company has never filed a periodic report with the SEC, so its SEC industry code was never reviewed against one. | None on EDGAR |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-10-15 |
| Latest current report | 8-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 48 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +28.8% |
| 1 month | Not enough price history |
| 3 months | Not enough price history |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -45.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SANA | Sana Biotechnology Inc. | $1.88 | -6.93% | $563.3M |
| DNA | Ginkgo Bioworks Holdings Inc. | $8.50 | -11.55% | $551.0M |
| VALN | Valneva SE | $5.65 | -0.18% | $536.1M |
| ENTX | Entera Bio Ltd. | $3.02 | -2.89% | $525.9M |
| ETRA | Electra Therapeutics Inc. | $8.31 | -6.00% | $522.4M |
| SRZN | Surrozen Inc. | $32.32 | +2.25% | $616.1M |
| CGEM | Cullinan Therapeutics Inc. | $9.50 | -7.59% | $616.7M |
| FDMT | 4D Molecular Therapeutics Inc. | $11.29 | -7.69% | $636.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier